Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

[1]  M. Nurmohamed,et al.  Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement , 2018, Rheumatology.

[2]  M. Dougados,et al.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force , 2017, Annals of the rheumatic diseases.

[3]  U. Wagner,et al.  Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial , 2017, The Lancet.

[4]  M. Riesco,et al.  Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study , 2017, Arthritis Research & Therapy.

[5]  B. Gudbjornsson,et al.  The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. , 2016, Rheumatology.

[6]  B. Shea,et al.  International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials , 2016, Annals of the rheumatic diseases.

[7]  F. Perrotta,et al.  Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments , 2016, The Journal of Rheumatology.

[8]  D. Gladman,et al.  Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 , 2016, Annals of the rheumatic diseases.

[9]  C. Lee,et al.  THU0440 Ixekizumab Provides Sustained Improvement up To 52 Weeks of Disease Activity as Assessed by Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug (bDMARD)-Naive Patients with Active Psoriatic Arthritis , 2016 .

[10]  A. Kavanaugh,et al.  Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey , 2016, Rheumatology and Therapy.

[11]  L. Coates,et al.  Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study , 2016, Arthritis care & research.

[12]  L. Coates,et al.  Treating to target in psoriatic arthritis: how to implement in clinical practice , 2015, Annals of the rheumatic diseases.

[13]  D. Gladman.  Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. , 2015, Rheumatic diseases clinics of North America.

[14]  J. Smolen,et al.  Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. , 2015, Clinical and experimental rheumatology.

[15]  M. D. de Wit,et al.  A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative , 2014, Annals of the rheumatic diseases.

[16]  L. Coates,et al.  Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial , 2014, The Lancet.

[17]  A. Armstrong,et al.  Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis , 2014, Drugs.

[18]  A. Menter,et al.  Burden of Disease: Psoriasis and Psoriatic Arthritis , 2013, American Journal of Clinical Dermatology.

[19]  L. Coates,et al.  The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis , 2013, BMC Musculoskeletal Disorders.

[20]  P. Mease.  Psoriatic arthritis: update on pathophysiology, assessment and management , 2011, Annals of the rheumatic diseases.

[21]  L. Coates,et al.  Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort , 2010, Arthritis care & research.

[22]  L. Coates,et al.  Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data , 2010, Arthritis care & research.

[23]  L. Coates,et al.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment , 2009, Annals of the rheumatic diseases.

[24]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[25]  P. Helliwell,et al.  Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. , 2001, The Journal of rheumatology.

[26]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[27]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[28]  Mark Oppe,et al.  EQ-5D value sets : inventory, comparative review, and user guide , 2007 .

[29]  M. Sullivan,et al.  Do SF-36 summary component scores accurately summarize subscale scores? , 2004, Quality of Life Research.